Aged mice related models are based on animals that begin to exhibit cognitive, biochemical and brain metabolism deficits starting at approximately 12 months of age.
These models can be used to assess efficacy in age-related cognitive decline associated with Parkinson’s, Alzheimer’s diseases and other diseases linked with aging. These studies can also be combined with other models such as scopolamine-induced amnesia.
The need for better animal models in aging preclinical research is based on the necessity to reduce first clinical phases high attrition rate. Indeed, how does one explain the discrepancy between positive preclinical results and failure in early clinical phases? The translation value is too low.
Our answer: animal models need to better mimic the development of the human disease.
Our new available models for Parkinson’s disease integrate the major known risk factors in the development of the disease:
Behavioral (Pole test, Rota-Rod test, Force Swim test, Social Recognition test, Open field activity test…) as well as histology studies show that these models correctly recapitulate the physiopathology of the human disease. In particular, we observed in old animals, after LPS triggered inflammation and MPTP chronic treatment, the formation of α-synuclein aggregates and a reduction in Tyrosine Hydroxylase positive neurons.
We anticipate that these animal models will prove useful to better predict human response to tested items.
At Pharmaseed, Not Young But Relevant is more than a new animal model, it is an ongoing discussion on the latest scientific results, news and views to improve neurodegenerative diseases clinical attrition rate: from new available models to basic research reproducibility issues.
If you want to follow our news and enter the discussion, you are welcome to join our Pharmaseed Translational Group on Linked In.
For more information, please visit: